Pfizer FDA Regulatory Challenges - Search News

News

FDA Will Approve COVID-19 Vaccine

Reuters on MSN · 4d

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under age 65, effectively limiting them to older adults and those at risk of developing severe illness.

Devdiscourse · 7d

FDA Grants Conditional Approval to Novavax's COVID-19 Vaccine

The U.S. FDA approved Novavax's COVID-19 vaccine with conditions, allowing use for people 65 and older and those 12-64 with underlying conditions. The FDA delayed pediatric studies. The approval marks a significant milestone despite initial delays and challenges faced by Novavax due to manufacturing issues.

FDA Approves New Covid Vaccine

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

5d

Pfizer: Better To Face The Harsh Reality Than Continue Waiting

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

After FDA Cuts, Planning for Upcoming ODAC Meeting Has Been ‘Absolute Chaos’

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

Novavax shares jump after long-awaited FDA approval of COVID-19 vaccine

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results